Advanced Biomed Inc., an investment holding company, engages in the research and development of microfluidic biochip technologies for precision oncology detection, diagnosis, and treatment in Taiwan. It offers A+Pre, a device that prepares blood samples for testing; the AC-1000, a device that separates cancer cells from the rest of the blood; A+SCDrop, a device that isolates individual cells; and A+CellScan, a device that stains and automatically counts cancer cells. The company provides developed dye kits used to identify different types of cancer cells. It also offers FinTruth financial verification agent platform, an enterprise AI financial verification platform designed to compare and verify financial analysis and AI-generated financial content against underlying source documents and financial rules, and to produce source-traceable and auditable results. The company was founded in 2014 and is based in Tsuen Wan, Hong Kong.